EarningsQ2 2026 Earnings Report
CH:HTD Q2 2026 EPS Results
Actual EPSCHF0.30
Consensus EPSCHF0.02
Beat/MissBeat by +CHF0.28
One Year Ago EPSCHF0.24
CH:HTD Q2 2026 Revenue Results
Actual RevenueCHF212.70M
Expected RevenueCHF183.64M
Beat/MissBeat by +CHF29.06M
YoY Revenue Growth+31.74%
Earnings Announcement Details
QuarterQ2 2026
Date07/29/2026
TimeAfter Close
Conference CallWednesday, July 29, 2026
CH:HTD Upcoming Earnings
Corcept Therapeutics's next earnings date is estimated for November 4, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
CH:HTD Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights robust commercial momentum and meaningful clinical and regulatory progress: strong Q2 financials (+32% revenue growth), a fast and well‑covered Lifyorli launch with survival data supporting uptake, record Korlym prescribing driven by shifting clinical awareness, and multiple near‑term trial readouts. Offsetting these positives are residual regulatory risk for relacorilant (prior CRL, PDUFA Dec 17, 2026), tolerability concerns and mixed statistical significance in early ALS results, and the usual clinical/regulatory execution risks across the pipeline. On balance, the positive financial performance, rapid oncology launch, and pipeline catalysts outweigh the noted risks.Company Guidance
Strong Revenue Growth
Total revenue for Q2 2026 was $256.0 million, a 32% increase year-over-year. Korlym + authorized generic revenue were $208.6 million and Lifyorli generated $47.6 million in its first quarter of availability.
Improved Profitability and Cash Position
Net income rose to $43 million in Q2 2026 from $35 million in the prior-year period (≈23% increase). Cash and investments totaled $545 million at June 30, 2026. Operating expenses were flat versus Q1 2026.
Raised 2026 Revenue Guidance
Company increased 2026 revenue guidance to a range of $1.1 billion to $1.2 billion, citing strength across both endocrinology (Korlym) and oncology (Lifyorli) businesses.
Lifyorli Launch: Rapid Uptake and Market Access
Lifyorli received FDA approval March 25 and launched April 1. Over 1,300 patients have started therapy and more than 1,000 unique prescribers have written prescriptions. More than 70% of combined Medicare, Medicaid and commercial lives have formal coverage policies. NCCN listed Lifyorli as a preferred regimen within 15 days of approval, supporting rapid adoption.
ROSELLA Trial — Survival Benefit for Lifyorli
In the pivotal ROSELLA trial, Lifyorli plus nab‑paclitaxel produced a 35% reduction in risk of death (hazard ratio 0.65) versus nab‑paclitaxel alone; p=0.04. Company cites these results as a driver of physician demand and early-line adoption.
Korlym / Cushing's Franchise Momentum
Company reported record numbers of new prescriptions, first‑time prescribers and active patients on Korlym. Management projects the current Cushing's syndrome business to reach at least $2 billion in annual revenue by the end of the decade, and, with relacorilant, projects $3–$5 billion (company projection).
Clinical Evidence Driving Increased Screening
Catalyst and MOMENTUM trials are shifting practice: Catalyst found a 24% prevalence of hypercortisolism in difficult‑to‑treat diabetes and 39.7% prevalence in patients with both resistant diabetes and resistant hypertension; MOMENTUM screened >1,000 resistant hypertension patients and found 27% had hypercortisolism (32.6% in a cited subgroup). Catalyst results were published in Diabetes Care and referenced in AACE guidance, increasing physician awareness.
Regulatory Progress for Relacorilant
Following a prior complete response letter (CRL), the company completed additional analyses, resubmitted the relacorilant NDA on June 17, 2026, and the FDA accepted the resubmission with a PDUFA date of December 17, 2026.
Broad Development Pipeline with Multiple Near‑Term Readouts
Multiple oncology and non‑oncology trials are underway with expected near‑term data: BELLA arm results in platinum‑resistant ovarian cancer and MONARCH Phase 2b MASH results later this year; BELLA/STELLA/TRIDENT and Synergy (miricorilant + nivolumab) readouts expected by end of next year, supporting potential expansion of indications.
CH:HTD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed